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original work is propObjective: Atazanavir (ATV) and lopinavir (LPV) have been associated with kidney
disease progression in HIV positive patients, with no data reported for darunavir (DRV).
We examined kidney function in patients who switched their protease inhibitor from
ATV or LPV to DRV.
Design: Cohort study.
Methods: Data were from the UK CHIC study. We compared pre and post switch
estimated glomerular filtration rate (eGFR) slopes (expressed in ml/min per 1.73m2 per
year) in all switchers and those with rapid eGFR decline (>5ml/min per 1.73m2 per
year) on ATV or LPV. Mixed-effects models were adjusted for age, gender, ethnicity,
eGFR at switch and time updated CD4þ cell count, HIV RNA and cumulative tenofovir
(tenofovir disoproxil fumarate) exposure.
Results: Data from 1430 patients were included. At the time of switching to DRV,
median age was 45 years, 79% were men, 76% had an undetectable viral load, and
median eGFRwas 93ml/min per 1.73m2. Adjustedmean (95% confidence interval) pre
and post switch eGFR slopes were0.84 (1.31, 0.36) and 1.23 (0.80, 1.66) for ATV
(P<0.001), and0.57 (1.09,0.05) and 0.62 (0.28, 0.96) for LPV (P<0.001). Stable
or improved renal function was observed in patients with rapid eGFR decline on ATV or
LPV who switched to DRV [15.27 (19.35, 11.19) and 3.72 (1.78, 5.66), P<0.001
for ATV, 11.93 (14.60, 9.26) and 0.87 (0.54, 2.27), P<0.001 for LPV]. Similar
results were obtained if participants who discontinued tenofovir disoproxil fumarate at
the time of switch were excluded.
Conclusions: We report improved kidney function in patients who switched from ATV
or LPV to DRV, suggesting that DRV may have a more favourable renal safety profile.
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Antiretroviral therapy (ART) allows people living with HIV
to achieve a normal life expectancy [1]. Widespread use of Copyright © 2017 Wolters Kluwe
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486 AIDS 2017, Vol 31 No 4population, and important causes of death [2–4]. The
potential contribution of ART to the burden of CKD has
been the focus of several large observational cohort studies;
tenofovir disoproxil fumarate (TDF), atazanavir (ATV) and
lopinavir (LPV) have been associated with incident CKD
and CKD progression in these studies [5–7], although the
magnitude of the reported associations was relatively modest
(14–16%, 20–21%, and 8–11% increased incidence of
CKD with each additional year of exposure to TDF, ATV,
and LPV) [5,6]. A possible explanation for these observed
associations may be that TDF can give rise to acute tubular
injury and ATV to kidney stone formation and interstitial
nephritis [8–10]. In addition, infrequent reports have linked
LPVand ritonavir (RTV) to acute kidney injury and stone
formation [11–13]. By contrast, long-term renal safety data
for darunavir (DRV) are sparse and it remains unclear
whether the observed association of ATV and LPV with
CKD reflects a protease inhibitor class effect, or whether
DRVis awell tolerated treatmentoption for patientswith, or
at risk of CKD and kidney disease progression. RTV is an
inhibitor of P-glycoprotein, the cytochrome P450 system
that boosts the plasma concentrations of LPV, ATV, and
DRV, and several renal tubular transporters involved in the
clearance of drugs and secretion of creatinine [14]. Reduced
tubular secretion of creatinine results in small increases in
plasma creatinine and, thereby, modest reductions in
estimated glomerular filtration rate (eGFR) [14]. Such
changes, which are typically acute (<4 weeks) in onset,
nonprogressive during follow-up and nontreatment limiting
[15], may affect the ability to accurately study kidney disease
progression in patients who receive protease inhibitor
therapy. This confounding effect, however, can be
minimized by studying serial eGFR in patients who switch
between boosted protease inhibitor.
We analysed eGFR slopes in patients who switched their
RTV-boosted protease inhibitor from ATV or LPV to
DRV and, based on our earlier work [16], hypothesised
that there would be no difference between pre and post
switch eGFR slope. We performed several planned
subgroup analyses to examine the effect of TDF
coexposure and the presence of rapid eGFR decline or
CKD prior to switching to DRV.Methods
We used data from the UK CHIC Study of HIV-positive
people who have accessed HIVoutpatient care at any of the
participating clinics since 1996 [17]. Individuals were
included if they switched from either ATVor LPV to DRV
(each boosted with RTV) at any point during follow-up and
had at least 6-months exposure to and more than two serum
creatinine measurements on the relevant protease inhibitor
pre and post switch. We allowed DRV to be started no more
than 7 days after discontinuation of ATV or LPV. Study
participants were followed from the time of starting either Copyright © 2017 Wolters Kluwer HATV or LPV to the earliest of DRV discontinuation, the
date of last follow-up in UK CHIC, or 31 December 2013.
Clinical characteristics at the time of protease inhibitor
switch were described for those that switched from ATVor
LPV to DRV. The CKD-EPI formulation was used to
convert creatinine measurements to eGFR [18]. To
estimate and compare the rate of eGFR change per year
before and after protease inhibitor switch, piecewise mixed
effects models with random intercept and time terms were
fitted with eGFR as the dependent variable. The effect of
time was allowed to change pre and post protease inhibitor
switch, thereby allowing estimation of pre and post switch
eGFR slopes. Mixed effects models were adjusted for the
following factors: age at switch, gender, ethnicity (white,
black, other/unknown), eGFR at switch and time updated
CD4þ cell count, HIV RNA [undetectable (<50 copies/
ml), detectable] and cumulative TDF use (where appro-
priate). Separate models were fitted for those on ATV or
LPV. eGFR slopes were also estimated in a group of
individuals exposed to either ATV or LPV who did not
switch to DRV, to provide context to our findings. These
individuals were also required to have at least 6- months
exposure to the protease inhibitor in question with at least
two serum creatinine measurements during this time.
Rapid eGFR decline was defined as a decline in eGFR of
more than 3 and more than 5 ml/min per 1.73 m2 per year
as estimated from unadjusted pre switch eGFR slopes in
the mixed effects model. Subgroup analyses were
performed that restricted analyses to those with rapid
eGFR decline, restricted to those with an eGFR less than
60 ml/min per 1.73 m2 prior to switching, excluded those
who also discontinued TDF at the time of protease
inhibitor switch and estimated eGFR slopes separately for
those with and without TDF use prior to switching. In
sensitivity analyses, we estimated pre and post switch
eGFR slopes after excluding eGFR measurements in the
first 4 weeks of starting the ATV, LPV, and DRV-
containing regimens, excluding the last eGFR prior to
switch, and restricting eGFR measurements to only
2 year of follow-up either side of the protease inhibitor
switch. To provide context, eGFR slopes were also
estimated for individuals in the UK CHIC Study who
commenced ATV or LPV for at least 6 months and who
did not switch to DRV, provided they had at least two
creatinine measurements during the period of ATV or
LPVexposure. For any individual satisfying these criteria
at more than one time point, the first episode was used.Results
A total of 2667 people switched from either LPV/RTVor
ATV/RTV to DRV/RTV during UK CHIC follow-up.
Of these, 1894 had at least 6-months follow-up on the
protease inhibitor pre and post switch and 1430 also had at
least two creatinine measurements available during theealth, Inc. All rights reserved.
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Table 1. Patient characteristics at switch from atazanavir (/r) or lopinavir (/r) to darunavir (/r).
Lopinavir switch Atazanavir switch Any switch
Characteristics N¼853 N¼577 N¼1430
Age
Years 45 (40, 51) 45 (39, 51) 45 (40, 51)
Sex
Male 671 (78.7) 463 (80.2) 1134 (79.3)
Female 182 (21.3) 114 (19.8) 296 (20.7)
Ethnicity
White 593 (69.5) 407 (70.5) 1000 (69.9)
Black 204 (23.9) 123 (21.3) 327 (22.9)
Other/unknown 56 (6.6) 47 (8.2) 103 (7.2)
Exposure
Sex between men 538 (63.1) 375 (65.0) 913 (63.9)
Heterosexual 261 (30.6) 166 (28.8) 427 (29.9)
Other/unknown 54 (6.3) 36 (6.2) 90 (6.3)
Year
2005–2009 399 (46.8) 248 (43.0) 767 (45.2)
2010–2013 454 (53.2) 329 (57.0) 924 (54.8)
CD4þ cell count
cells/ml 517 (349, 728) 510 (367, 705) 513 (359, 719)
Viral load
Detectable (>50) 189 (22.2) 151 (26.2) 340 (23.8)
Undetectable (<50) 661 (77.8) 425 (73.8) 1086 (76.2)
NRTI backbone
TDF-containing 501 (58.7) 419 (72.6) 920 (64.3)
non-TDF 204 (23.9) 115 (19.9) 319 (22.3)
None 148 (17.4) 43 (7.5) 191 (13.4)
Other PI use
No 722 (84.6) 619 (91.7) 1251 (87.5)
Yes 131 (15.4) 48 (8.3) 179 (12.5)
NNRTI use
No 750 (87.9) 534 (92.6) 1284 (89.8)
Yes 103 (12.1) 43 (7.5) 146 (10.2)
eGFR
<60 57 (6.7) 72 (12.5) 129 (9.0)
60–75 106 (12.4) 90 (15.6) 196 (13.7)
75–90 202 (23.7) 127 (22.0) 329 (23.0)
>90 488 (57.2) 128 (49.9) 776 (54.3)
ml/min per 1.73m2 94 (79, 107) 90 (74, 106) 93 (77, 107)
eGFR, estimated glomerular filtration rate; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor;
PI, protease inhibitor; TDF, tenofovir disoproxil fumarate. Data are shown as N (%) except age and CD4þ cell count which are shown as median
(interquartile range).pre and post switch periods. The characteristics of the 577
patients who switched from ATV to DRV and the 853
patients who switched from LPV to DRV were broadly
similar (Table 1). The earliest switch in the UK CHIC
data set occurred in 2005, and the median year of protease
inhibitor switch was 2010. The median age at switch was
45 years; ART exposure was extensive (median duration
10.1 years), 920 study participants (64%) were on TDF,
and 76% had an undetectable viral load at the time of
switching. A total of 647 (45.2%) individuals made
changes to another aspect of their ART regimen at the
time of the protease inhibitor switch. A nucleoside
reverse transcriptase inhibitor (NRTI) was switched,
discontinued, or added to the regimens of 158 (11.0%),
352 (24.6%), and 51 (3.6%) people, respectively; 236
(16.5%) discontinued TDF. Changes involving a non-
nucleoside reverse transcriptase inhibitor (NNRTI) were
made in 183 (12.8%) individuals and 133 (9.3%) changed
another ARV, such as an entry or fusion inhibitor. The
median (interquartile range, IQR) eGFR at switch was
90 (74, 106) ml/min per 1.73 m2 in the ATV group Copyright © 2017 Wolters Kluweand 94 (79, 107) ml/min per 1.73 m2 in the LPV group.
The median (IQR) duration of ATV and LPV exposure
was 3.1 (1.6, 4.7) and 4.1 (2.2, 6.8) years, and the
median duration of DRV exposure 2.6 (1.6, 3.8) and 3.0
(2.0, 4.2) years, respectively.
The mean eGFR slope estimates of people who switched
from ATVor LPV to DRVare shown in Table 2. A small
annual decline in eGFR prior to switch was observed
during exposure to ATV or LPV. The eGFR slopes
improved significantly after these patients switched their
protease inhibitor to DRV. Estimated eGFR slopes pre
and post switch remained similar after adjusting for a-
priori factors mentioned previously. A decline in eGFR
was still observed prior to switch [0.84 (1.31, 0.36)
and 0.57 (1.09, 0.05) ml/min per 1.73 m2 per year
for ATV and LPV], with improvement in eGFR post
switch [1.23 (0.80, 1.66) and 0.62 (0.28, 0.96) ml/min
per 1.73 m2 per year for ATV and LPV, respectively].
Declines in eGFR were also observed in 6955 study
participants exposed to ATVor LPV for at least 6 monthsr Health, Inc. All rights reserved.
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Table 2. eGFR slope estimates in individuals who switch from either atazanavir (/r) or lopinavir (/r) to darunavir (/r).
Mean change in eGFR per year (95% CI)
Regimen N Pre switch Post switch P valueM
A. All switchers
Unadjusted estimates
All switchers 1430 0.87 (1.21, 0.53) 0.51 (0.25, 0.77) <0.001
Atazanavir 577 0.94 (1.38, 0.49) 0.90 (0.47, 1.34) <0.001
Lopinavir 853 0.78 (1.29, 0.28) 0.27 (0.05, 0.59) <0.001
Adjusted estimatesMM
All switchers 1430 0.67 (1.03, 0.31) 0.86 (0.59, 1.12) <0.001
Atazanavir 577 0.84 (1.31, 0.36) 1.23 (0.80, 1.66) <0.001
Lopinavir 853 0.57 (1.09, 0.05) 0.62 (0.28, 0.96) <0.001
Mean change in eGFR per year (95% CI)
Regimen N Pre switch Post switch P valueM
B. Excluding individuals who discontinued TDF at the time of PI switchMM
Atazanavir 443 0.45 (1.00, 0.09) 0.79 (0.30, 1.27) 0.002
Lopinavir 751 0.44 (1.03, 0.16) 0.62 (0.26, 0.99) 0.004
Mean change in eGFR per year (95% CI)
Regimen N Pre switch Post switch P valueM
C. Patients who received TDF prior to switch (regardless of TDF use post switch)y
Atazanavir 419 1.27 (1.80, 0.74) 1.37 (0.85, 1.88) <0.001
Lopinavir 501 1.26 (1.58, 0.95) 0.33 (0.07, 0.73) <0.001
Mean change in eGFR per year (95% CI)
Regimen N Pre switch Post switch P valueM
D. Patients who did not receive TDF prior to switch (regardless of TDF use post switch)y
Atazanavir 158 0.22 (1.17, 0.72) 0.51 (0.20, 1.22) 0.240
Lopinavir 351 0.20 (1.25, 1.66) 0.52 (0.04, 1.09) 0.695
Slopes are measured in ml/min per 1.73m2 per year. CI, confidence interval; eGFR, estimated glomerular filtration rate; PI, protease inhibitor; TDF,
tenofovir disoproxil fumarate.
MPre vs. post switch eGFR slopes.
MMModel includes age, sex, ethnicity, eGFR at switch, CD4þ count, undetectable viral load (yes/no) and cumulative TDF exposure.
yModel includes age, sex, ethnicity, eGFR at switch, CD4þ count and undetectable viral load (yes/no).(with at least two eGFR measurements) who did not
switch to DRV; 0.51 (-0.67, -0.34; ATV) and 0.76
(0.94, 0.59; LPV) ml/min per 1.73 m2 per year,
respectively.
Exclusion of the 236 study participants on ATV or LPV
who also discontinued TDF at the time of protease
inhibitor switch resulted in more moderate but still
significantly different pre and post switch eGFR slopes
(Table 2b). When split by TDF use prior to switch, eGFR
slope estimates for those who received ATVor LPV with
TDF were similar to those in the main analysis, with a
significant difference in pre and post switch estimates
(Table 2c). By contrast, the pre and post switch slope
estimates were not significantly different amongst study
participants who received ATV or LPV without TDF
(Table 2d). Sensitivity analyses excluding eGFR measure-
ments in the first 4 weeks of both the pre and post switch
regimens, excluding the last eGFR prior to switch and Copyright © 2017 Wolters Kluwer Hconsidering only 2-year follow-up either side of switch-
ing did not affect our results (data not shown).
Wethenanalysedthechanges ineGFRslopes inpatientswho
switchedtoDRVwithadverserenalprofilesonATVorLPV.A
total of 205 (14.3%) study participants had eGFR decline
more than 3 ml/min per 1.73 m2 per year, 92 (6.4%) had
eGFRdeclinemore than5ml/minper1.73 m2 per year, and
129 (9.0%) patients had eGFR less than 60 ml/min per
1.73 m2priortoswitch.Asexpected,muchsteeperpreswitch
eGFR decline was observed in these patients as compared
with the overall switch cohort (Table 3). Interestingly, the
mean eGFR slopes dramatically improved post switch, with
eGFR recovery during DRVexposure in several subgroups
and stabilisation of renal function in the remainder. Similar
results were obtained if the analyses were restricted to study
participants with adverse eGFR profiles who did not
discontinue TDF at the time of protease inhibitor switch
(Supplementary Table, http://links.lww.com/QAD/B23).ealth, Inc. All rights reserved.
Renal function changes with protease inhibitor switch Jose et al. 489
Table 3. eGFR slope estimates in patients with rapid eGFR decline or eGFR more than 60 on atazanavir (/r) or lopinavir (/r).
Mean change in eGFR per year (95% CI)
Regimen N Pre switch Post switch P valueM
Rapid eGFR decline (>3ml/min per 1.73m2): unadjusted estimates
Atazanavir 94 10.12 (11.95, 8.29) 1.68 (0.16, 3.20) <0.001
Lopinavir 111 7.99 (9.01, 6.96) 0.42 (0.46, 1.31) <0.001
Rapid eGFR decline (>3 ml/min per 1.73m2): adjusted estimatesy
Atazanavir 94 9.69 (11.51, 7.88) 2.37 (1.08, 3.67) <0.001
Lopinavir 111 7.28 (8.39, 6.18) 0.92 (0.03, 1.82) <0.001
Rapid eGFR decline (>5 ml/min per 1.73m2): unadjusted estimates
Atazanavir 48 15.25 (19.22, 11.27) 2.91 (0.69, 5.12) <0.001
Lopinavir 44 13.17 (15.72, 10.61) 0.51 (0.99, 2.01) <0.001
Rapid eGFR decline (>5 ml/min per 1.73m2): adjusted estimatesy
Atazanavir 48 15.27 (19.35, 11.19) 3.72 (1.78, 5.66) <0.001
Lopinavir 44 11.93 (14.60, 9.26) 0.87 (0.54, 2.27) <0.001
eGFR <60 ml/min per 1.73m2: unadjusted estimates
Atazanavir 72 7.10 (9.67, 4.53) 3.21 (1.65, 4.77) <0.001
Lopinavir 57 3.51 (5.13, 1.90) 2.52 (0.44, 4.60) <0.001
eGFR <60 ml/min per 1.73m2: adjusted estimatesy
Atazanavir 72 6.29 (8.68, 3.90) 3.40 (1.82, 4.98) <0.001
Lopinavir 57 2.60 (4.05, 1.15) 2.56 (0.40, 4.72) <0.001
Slopes are measured in ml/min per 1.73m2 per year. CI, confidence interval; eGFR, estimated glomerular filtration rate; PI, protease inhibitor; TDF,
tenofovir disoproxil fumarate.
MPre vs. post switch eGFR slopes.
yModel includes age, sex, ethnicity, eGFR at switch, CD4þ cell count, undetectable viral load (yes/no) and cumulative TDF exposure.Discussion
Contrary to our hypothesis, patients in the UK CHIC
cohort who switched their protease inhibitor from ATV
or LPV to DRV experienced small but statistically
significant improvements in renal function. The improve-
ments in eGFR slope were observed in patients who
received ATV or LPV with TDF and much more
pronounced in study participants who had experienced
rapid eGFR decline or renal impairment prior to protease
inhibitor switch. Our data suggest that ATV and LPV,
especially when coadministered with TDF, may result in
kidney injury and that switching these protease inhibitor
to DRV may preserve renal function.
The effects of ATV and DRV on kidney function have
been compared in several studies. Two randomized
controlled clinical trials of ART-naı¨ve patients who
initiated ATVor DRV with RTV, TDF, and emtricitabine
(FTC) reported similar changes in creatinine clearance or
eGFR [19,20], and another trial a similar incidence
(7/556 vs. 12/546) of grade 3 or 4 elevations in serum
creatinine at 96 weeks [21]. A cross-sectional study
reported similar proportions of patients on ATVand DRV
having crystalluria (8.9 and 7.8%, respectively) [22]. By
contrast, a Japanese retrospective study noted a consider-
ably greater incidence of nephrolithiasis with ATV as
compared with DRV [incidence rate 20.2 vs. 0.86 per
1000 person-years, hazard ratio 21.5 (95%confidence
interval 2.9, 160)] [23]. The effects of LPV and DRV on
the kidney have also been compared in a randomized
controlled clinical trial. Patients in the ARTEMIS trial
who received LPV or DRV with RTV and TDF/FTC
experienced similar changes in creatinine clearance, renal Copyright © 2017 Wolters Kluweadverse events and kidney stones [24]. Differences
between clinical trial and cohort populations, with
high-risk populations generally excluded from participat-
ing in clinical trials, and limited power to detect small
differences in eGFR slope (<1 ml/min per 1.73 m2 per
year) may potentially explain the disparate results between
the randomized controlled trial data and our observa-
tional cohort data, underscoring the importance of both
types of studies to detect potential adverse effects of ART
on the kidney. The small sample size (n¼ 47) and the
inclusion of study participants who received LPV (74%)
or a non-TDF regimen (37%) may explain why our
earlier study failed to show a change in eGFR slope
following protease inhibitor switch to ATV [16].
Interestingly, improved kidney function (assessed by
plasma cystatin C) has been reported in a small pilot study
in which 13 study participants changed their ART
regimen from LPV (or fosamprenavir) to DRV [25].
In our study, the majority of patients who received ATV
or LPV without TDF had stable renal function pre switch
and no significant improvement in eGFR post switch,
suggesting that these drugs per se have limited nephrotoxic
potential [14]. Several studies have noted an adverse effect
of TDF and protease inhibitor coadministration on the
kidney: in ACTG 5202, eGFR decline was reported in
study participants who were randomized to ATV with
TDF/FTC but not in those who received ATV with
abacavir/lamivudine (ABC/3TC) or efavirenz with
TDF/FTC or ABC/3TC [26], and in CCTG 578,
study participants randomized to receive TDF with a
protease inhibitor (rather than an NNRTI) experienced
greater eGFR decline [27]. Furthermore, discontinuation
of TDF may result in considerable improvement in renalr Health, Inc. All rights reserved.
490 AIDS 2017, Vol 31 No 4function, with eGFR returning to pre-TDF values in
approximately three quarters of patients [28].
We defined rapid eGFR decline using an average rate of
decline over the period on ATV or LPV, based on the
results of mixed-effects models and a minimum of 6-
months exposure to these drugs. The definition of rapid
progression proposed by D:A:D requires extensive (at
least 3 year) follow-up and at least two creatinine measures
per year, and was applied to individuals with eGFR at
least 90 ml/min per 1.73 m2 in the original study [29].
When these more stringent criteria were applied to our
study population, only 140 individuals met the definition
of rapid eGFR decline. In their study, the authors
acknowledge the potential for selection bias introduced
by requiring a minimum of 3-year of follow-up and the
exclusion of patients with eGFR 90 ml/min per 1.73 m2
or less at baseline. Indeed, the described changes in eGFR
slope in our study are likely to be of greatest clinical
significance in the group of participants who already
had impaired renal function prior to initiating ATV
or LPV.
Our study was well powered to examine pre and post
switch differences in eGFR slope. By restricting the
analyses to patients who received RTV-boosted protease
inhibitor, we eliminated the effect of RTV on tubular
creatinine secretion. However, some limitations need to be
acknowledged. The UK CHIC study has incomplete data
on the reasons for ART switches and no data on
comorbidities and concomitant medications which could
have affected eGFR. We had to exclude almost half of all
study participantswho switched from ATVor LPV to DRV
because of insufficient eGFR data to construct slopes for
comparison. As creatinine was measured in local
laboratories, we are unable to exclude small intersubject
differences in creatinine measurements. Finally, by nature
of observational cohort studies, we are unable to exclude
that bias or confounding may have affected our results and
cannot directly attribute the observed improved eGFR
slope patterns to the switch from ATV or LPV to DRV.
HIV-positive patients with CKD currently have limited
ARToptions. Tenofovir alafenamide was recently shown
to be safe and effective in patients with stable, impaired
renal function (creatinine clearance as low as 30 ml/min)
[30]. In the absence of randomized clinical trial data on
boosted protease inhibitor in renally impaired persons,
our data suggest that ATVand LPV may be best avoided in
patients with (or at risk of developing) CKD, especially if
they require continued use of TDF, and that DRV may be
the protease inhibitor of choice for this population.Acknowledgements
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